Lykos accepts FDA’s view that reviving rejected MDMA therapy’s fortunes requires fresh phase 3 trial
Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...
In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...
The FDA has indicated a path forward for the first psychedelic-assisted therapy, its developer which failed to win approval ...
As Massachusetts prepares to vote on a measure that would legalize psilocybin and other plant-based psychedelic substances, ...
The FDA recently declined to approve MDMA-assisted therapy for PTSD, but experts said there are many other treatments on the ...
Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...
Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company ...
Why Harris-Walz? The women say they believe Donald Trump, the Republican candidate, would reduce funding for Medicaid and Medicare spending and repeal the Affordable Care Act. They say that would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback